Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Pancreatic Cancer: Side Effect Of Onglyza, Nesina, Tradjenta, Other DPP-4 Inhibitor Diabetes Drugs?

September 26, 2019 By Law Offices of Thomas J. Lamb, P.A.

There is new medical research concerning pancreatic cancer linked to diabetes medicines in the DPP-4 inhibitor drug class.

In more detail, the use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines may be associated with an increased risk for pancreatic cancer in patients with newly diagnosed type 2 diabetes. This finding comes from an August 20, 2019 article published online by the Diabetes Care medical journal.

Some of the more popular diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class are Onglyza (saxagliptin), Nesina (alogliptin), and Tradjenta (linagliptin).

From the Abstract for this Diabetes Care article, “Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase-4 Inhibitors”, we get the following information:

CONCLUSIONS: DPP-4i use is associated with increased risks of pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes. However, the absence of increasing trend according to exposure duration suggests the chances of reverse causality, and long-term pancreatic safety of DPP-4i has to be further investigated.

We are watching for further developments about pancreatic cancer linked to diabetes medicines such as Onglyza, Nesina, and Tradjenta, as well as other dipeptidyl peptidase-4 (DPP-4) inhibitor diabetes drugs.

[View article at original source]

Diabetes Drugs

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, diabetes drugs side effects, drug side effects, Nesina, Onglyza, Pancreatic Cancer, Tradjenta

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.